Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adre
Go back to Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adre| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 163.00 +1.38 (0.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $161.62 | 52 Week High | $58.46 | |||
| Open | $161.62 | 52 Week Low | $31.25 | |||
| Day High | $163.19 | P/E | N/A | |||
| Day Low | $161.35 | EPS | $-0.69 | |||
| Volume | 202,815 | |||||
